UB Paderborn / Katalog / Suche / in CDI

The Efficacy of Same Day Plerixafor Dosing on CD34+ Haematopoietic Stem Cell Collection: A Single Centre Australian Experience

Blood, 2022-11, Vol.140 (Supplement 1), p.12805-12805

2022

Volltextzugriff (PDF)

Hospital in the Home Delivery of Supportive Care for Autologous Stem Cell Transplantation: A Novel Single Centre Patient Focused Approach

Blood, 2021-11, Vol.138 (Supplement 1), p.1834-1834

2021

Volltextzugriff (PDF)

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two‐centre Australian experience

Internal medicine journal, 2021-02, Vol.51 (2), p.280-283

2021

Volltextzugriff (PDF)

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65years: a two‐centre Australian experience

Internal medicine journal, 2021-02, Vol.51 (2), p.280-283

2021

Volltextzugriff (PDF)

Favourable Outcomes for Carfilzomib-Melphalan and Bortezomib-Melphalan Conditioned Autologous Hematopoietic Stem Cell (AHCT) Transplants in Relapsed/Primary Refractory Myeloma: An Australian Single Centre Real-World Experience

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S386-S386

2024

Volltextzugriff (PDF)

A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation

Clinical infectious diseases, 2021-12, Vol.73 (11), p.e4269-e4277

2021

Volltextzugriff (PDF)

Outcomes of Autologous Stem Cell Transplantation (ASCT) in Elderly Multiple Myeloma (MM) Patients Aged ≥ 65 Years: A Multi-Centre Australian Experience

Blood, 2018-11, Vol.132 (Supplement 1), p.3441-3441

2018

Volltextzugriff (PDF)

Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre

Supportive care in cancer, 2022-02, Vol.30 (2), p.1841-1852

2022

Volltextzugriff (PDF)

NP-108: Improvement in patient experience with successful implementation of a Velcade at Home program in patients with myeloma

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S168-S169

2021

Volltextzugriff (PDF)

Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre

Supportive care in cancer, 2018-03, Vol.26 (3), p.997-1003

2018

Volltextzugriff (PDF)

The development of a home-based therapeutic platform for multiple myeloma

Expert review of hematology, 2021-12, Vol.14 (12), p.1129-1135

2021

Volltextzugriff (PDF)

Impact of an Allied Health Prehabilitation Service on Haematologic Cancer Patients Receiving Intensive Chemotherapy with Autologous Stem Cell Rescue: A Single Centre Observational Study

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S310

2021

Volltextzugriff (PDF)

The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation

Clinical lymphoma, myeloma and leukemia, 2014-08, Vol.14 (4), p.291-296

2014

Volltextzugriff (PDF)

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

Leukemia & lymphoma, 2013-07, Vol.54 (7), p.1465-1472

2013

Volltextzugriff (PDF)

Pharmacy switching in response to preferred pharmacy networks in Medicare Part D

Health services research, 2022-10, Vol.57 (5), p.1112-1120

2022

Volltextzugriff (PDF)

Physician Reimbursement in Medicare Advantage Compared With Traditional Medicare and Commercial Health Insurance

JAMA internal medicine, 2017-09, Vol.177 (9), p.1287

2017

Volltextzugriff (PDF)

Part D beneficiaries' incentives and responses under preferred pharmacy networks

The American journal of managed care, 2023-04, Vol.29 (4), p.180-186

2023

Volltextzugriff (PDF)

Sharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors

The New England journal of medicine, 2016-01, Vol.374 (4), p.384-386

2016

Volltextzugriff (PDF)

Incorporating Prescription Drug Utilization Information Into the Marketplace Risk Adjustment Model Improves Payment Accuracy and Reduces Adverse Selection Incentives

Medical care research and review, 2021-08, Vol.78 (4), p.381-391

2021

Volltextzugriff (PDF)

Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase

Health affairs (Millwood, Va.), 2016-09, Vol.35 (9), p.1564

2016

Volltextzugriff (PDF)

Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap

Health affairs (Millwood, Va.), 2018-07, Vol.37 (7), p.1048-6A

2018

Volltextzugriff (PDF)

Who Pays in Medicare Part D? Giving Plans More Skin in the Game

The New England journal of medicine, 2019-12, Vol.381 (25), p.2384-2387

2019

Volltextzugriff (PDF)

Sharing Clinical Trial Data: A Proposal from the International Committee of Medical Journal Editors

PLoS medicine, 2016-01, Vol.13 (1), p.e1001950-e1001950

2016

Volltextzugriff (PDF)

Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members

JAMA internal medicine, 2021-10, Vol.181 (10), p.1414

2021

Volltextzugriff (PDF)

Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D

JAMA network open, 2021-01, Vol.4 (1), p.e2033988-e2033988

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

The Efficacy of Same Day Plerixafor Dosing on CD34+ Haematopoietic Stem Cell Collection: A Single Centre Australian Experience

Hospital in the Home Delivery of Supportive Care for Autologous Stem Cell Transplantation: A Novel Single Centre Patient Focused Approach

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two‐centre Australian experience

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65years: a two‐centre Australian experience

Favourable Outcomes for Carfilzomib-Melphalan and Bortezomib-Melphalan Conditioned Autologous Hematopoietic Stem Cell (AHCT) Transplants in Relapsed/Primary Refractory Myeloma: An Australian Single Centre Real-World Experience

A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation

Outcomes of Autologous Stem Cell Transplantation (ASCT) in Elderly Multiple Myeloma (MM) Patients Aged ≥ 65 Years: A Multi-Centre Australian Experience

Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre

NP-108: Improvement in patient experience with successful implementation of a Velcade at Home program in patients with myeloma

Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre

The development of a home-based therapeutic platform for multiple myeloma

Impact of an Allied Health Prehabilitation Service on Haematologic Cancer Patients Receiving Intensive Chemotherapy with Autologous Stem Cell Rescue: A Single Centre Observational Study

The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

Pharmacy switching in response to preferred pharmacy networks in Medicare Part D

Physician Reimbursement in Medicare Advantage Compared With Traditional Medicare and Commercial Health Insurance

Part D beneficiaries' incentives and responses under preferred pharmacy networks

Sharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors

Incorporating Prescription Drug Utilization Information Into the Marketplace Risk Adjustment Model Improves Payment Accuracy and Reduces Adverse Selection Incentives

Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase

Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap

Who Pays in Medicare Part D? Giving Plans More Skin in the Game

Sharing Clinical Trial Data: A Proposal from the International Committee of Medical Journal Editors

Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members

Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D

Suchergebnisse filtern